直接口服抗凝药的实验室与临床监测:临床医生须知
本文综述直接口服抗凝药(DOACs)的监测策略,指出凝血监测一般仅推荐用于过量情况,标准化检测方法可用后有助于评估疗效、出血及药物选择。非凝血监测应包括血清肌酐、肝功能与全血细胞计数;临床监测应评估依从性、出血风险与药物相互作用。监测频率为起始后1-3个月,之后至少每6个月,并根据年龄、肾/肝损害及合并用药等患者特征调整。
要点
- 凝血监测一般仅推荐用于DOAC过量情况,标准化检测可用后可拓展应用场景。
- 非凝血监测应包括血清肌酐、肝功能与全血细胞计数。
- 临床监测应常规评估依从性、出血风险与药物相互作用。
核心结论
- DOACs凝血监测一般仅推荐用于过量情况,标准化检测可用后有助于确保疗效、评估出血及辅助药物选择。
- 临床与非凝血实验室监测应结合患者特征制定个体化方案,药师应与医生协作选择合适患者并制定监测计划。
研究设计与样本
- 本文为综述,针对达比加群、利伐沙班、阿哌沙班和艾多沙班等DOACs的实验室与临床监测进行论述。
主要发现
- DOACs与华法林相比疗效相等或更优且安全性改善,但半衰期较短需严格依从性,缺乏标准化实验室监测与常规凝血监测。
- 定性评估的凝血试验包括活化部分凝血活酶时间、凝血酶原时间和凝血酶时间。
- 定量评估方法包括血浆药物浓度、蛇静脉酶凝血时间、稀释凝血酶时间和抗Xa因子浓度。
关键数值与推荐
- 凝血监测一般仅推荐用于过量情况。
- 监测频率为起始后1-3个月,之后至少每6个月,基于年龄、肾损害、肝损害和合并用药等特征可每3个月更频繁随访。
- 非凝血实验室监测应包括血清肌酐、肝功能测试和全血细胞计数。
- 临床监测应包括常规评估依从性、出血风险和药物相互作用。
临床怎么用
- 药师应与医生协作选择合适患者并制定个体化监测计划。
- 根据患者年龄、肾/肝损害及合并用药等特征调整监测频率。
- 常规评估依从性、出血风险与药物相互作用,并监测血清肌酐、肝功能与全血细胞计数。
局限性
- DOACs缺乏标准化实验室监测方法与常规凝血监测,导致患者-临床医生互动减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The direct acting oral anticoagulants (DOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic properties and equal or superior efficacy and an improved safety profile compared with warfarin. Noted shortcomings with DOACs are shorter half-lives requiring stricter adherence, lack of standardized laboratory monitoring, lack of anticoagulation reversal agents, and loss of routine coagulation monitoring leading to fewer patient-clinician interactions. This review addresses many of these limitations including monitoring of DOACs for efficacy and toxicity, an assessment of selected qualitative and quantitative tests, and development of monitoring strategies for special populations. Coagulation monitoring is generally recommended only in overdose situations, but once standardized assays are readily available, they could be helpful to ensure efficacy, assess bleeding, and aid in drug selection in a number of other patient scenarios. Coagulation tests that may provide qualitative assessment include activated partial thromboplastin time, prothrombin time, and thrombin time. Methods with potential utility for quantitative assessment of DOACs include plasma drug concentrations, ecarin clotting time, dilute thrombin time, and anti-factor Xa concentrations. Noncoagulation laboratory monitoring should include serum creatinine, liver function tests, and complete blood counts. Clinical monitoring of the DOAC-treated patient should include routine assessment of adherence, bleeding risks, and drug interactions. Frequency of monitoring should be 1-3 months after initiation and then at least every 6 months, with more frequent follow-up (i.e., 3 months) based on patient specific characteristics such as age, renal impairment, hepatic impairment, and concomitant drug therapy. The authors provide a practical tool to assist in DOAC monitoring and recommend that pharmacists collaborate with physicians in selecting appropriate patients and tailoring patient-specific monitoring plans.
引用
- Conway SE, Hwang AY, Ponte CD, et al. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. Pharmacotherapy. 2017. PMID: 27983747. doi:10.1002/phar.1884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。